<DOC>
	<DOCNO>NCT02587351</DOCNO>
	<brief_summary>This multicenter , prospective , randomize , double-blind , placebo-controlled trial enroll 1028 patient least moderately severe COPD three year period follow regular interval one year . The primary endpoint time first acute exacerbation . Secondary endpoint include rate severity COPD exacerbation , cardiovascular event , all-cause mortality , lung function , dyspnea , quality life metoprolol-related side effect .</brief_summary>
	<brief_title>Beta-Blockers Prevention Acute Exacerbations Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>Hypothesis The primary hypothesis metoprolol succinate reduce risk COPD exacerbation compare placebo . The secondary hypothesis metoprolol succinate adversely impact lung function , exercise tolerance , dyspnea quality life compare placebo . Study Flow Patients screen randomize 2 week period undergo dose titration period follow six week . Thereafter patient follow 42 additional week target dose metoprolol placebo follow 4 week washout period . Specific Aims : Primary : To determine effect daily metoprolol succinate compare placebo time first exacerbation moderate severe COPD patient prone exacerbation absolute indication beta-blocker therapy . Secondary : To estimate effect metoprolol succinate compare placebo : 1 . The rate severity COPD exacerbations 12 month 2 . Incidence severity metoprolol-related side effect include require cessation drug 3 . Lung function assess spirometry , dyspnea assess Modified Medical Research Council Scale ( MMRC ) ( 45 ) San Diego Shortness Breath Questionnaire ( 46 , 47 ) , exercise tolerance measure six minute walk test ( 6MWD ) ( 48 ) , quality life assess Short Form 36 ( 49 ) , St. Georges Respiratory Questionnaire ( SGRQ ) ( 50 ) COPD Assessment Test ( CAT ) ( 51 ) Personal HEART Score ( 52 ) . 4 . Hospitalizations 5 . The rate major adverse cardiovascular event ( MACE ) ( define cardiovascular death , hospitalization myocardial infarction , heart failure , stroke ) , percutaneous coronary intervention coronary artery bypass graft 6 . All-cause mortality Secondary subgroup analyse 1 ) cardiovascular risk base Personal HEART Score 2 ) age great versus less 65 .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>1 . Male female subject , â‰¥ 40 less 85 year age 2 . Clinical diagnosis least moderate COPD define Global Initiative Obstructive Lung Disease ( GOLD ) criterion ( 53 ) : Post bronchodilator FEV1/FVC &lt; 70 % ( Forced expiratory volume 1 second/ force vital capacity ) , Post bronchodilator FEV1 &lt; 80 % predict , without chronic symptom ( i.e. , cough , sputum production ) . 3 . Cigarette consumption 10 packyears . Patients may may active smoker . 4 . To enrich population patient likely acute exacerbation ( 54 ) , subject must meet one follow 4 condition : Have history receive course systemic corticosteroid and/or antibiotic respiratory problem past year , Visiting Emergency Department COPD exacerbation within past year , Being hospitalize COPD exacerbation within past year Be use prescribed supplemental oxygen 12 hour per day Willingness make return visit availability telephone duration study . 1 . A diagnosis asthma establish study investigator basis recent American Thoracic Society/European Respiratory Society National Institute Health Care Excellence guideline . 2 . The presence diagnosis COPD result patient either medically unstable , predicted life expectancy &lt; 2 year . 3 . Women risk become pregnant study ( premenopausal ) refuse use acceptable birth control ( hormonebased oral barrier contraceptive ) duration study . 4 . Current tachy brady arrhythmia require treatment 5 . Presence pacemaker and/or internal cardioverter/defibrillator 6 . Patients history second third degree ( complete ) heart block , sick sinus syndrome 7 . Baseline EKG reveal leave bundle branch block , bifascicular block , ventricular tachyarrhythmia , atrial fibrillation , atrial flutter , supraventricular tachycardia ( sinus tachycardia multifocal atrial tachycardia ) , heart block ( 2nd degree complete ) 8 . Resting heart rate le 70 beat per minute , sustain rest tachycardia define heart rate great 120 beat per minute . 9 . Resting systolic blood pressure le 100mm Hg . 10 . Subjects absolute ( Class 1 ) indication betablocker treatment define combined American College Cardiology Foundation/American Heart Association Task Force Practice Guidelines , American College Physicians , American Association Thoracic Surgery , Preventive Cardiovascular Nurses Association , Society Cardiovascular Angiography Interventions , Society Thoracic Surgeons Guidelines include myocardial infarction , acute coronary syndrome , percutaneous coronary intervention coronary artery bypass surgery within prior 3 year patient know congestive heart failure define leave ventricular ejection fraction &lt; 40 % . ( 29 , 30 ) 11 . Critical ischemia relate peripheral arterial disease . 12 . Other disease know trigger betablockers betablocker withdrawal include myasthenia gravis , periodic hypokalemic paralysis , pheochromocytoma , thyrotoxicosis 13 . Patients cardiac medication know cause atrioventricular ( AV ) node conduction delay amiodarone , digoxin , calcium channel blocker include verapamil diltiazem well patient take clonidine . 14 . Hospitalization uncontrolled diabetes mellitus hypoglycemia within last 12 month . 15 . Patients cirrhosis 16 . A clinical diagnosis bronchiectasis define production &gt; onehalf cup purulent sputum/day . 17 . Patients otherwise meet inclusion criterion enrol minimum four week recent acute exacerbation ( i.e. , receive course systemic corticosteroid , increase dose chronically administer systemic corticosteroid , and/or antibiotic acute exacerbation minimum four week ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
	<keyword>Exacerbation</keyword>
	<keyword>Lung function</keyword>
	<keyword>Cardiac</keyword>
	<keyword>Cardiovascular</keyword>
	<keyword>Beta blocker</keyword>
	<keyword>Metoprolol succinate</keyword>
	<keyword>Smoking</keyword>
</DOC>